Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.

@article{Tomaka2009EffectsOR,
  title={Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.},
  author={Frank L. Tomaka and Eric A Lefebvre and Vanitha J. Sekar and Ben van Baelen and Tony J Vangeneugden and Ann Vandevoorde and G Diego Miralles},
  journal={HIV medicine},
  year={2009},
  volume={10 5},
  pages={318-27}
}
BACKGROUND Darunavir (TMC114) is a new HIV protease inhibitor (PI). DESIGN This Phase I, randomized, open-label trial compared the effects of darunavir plus low-dose ritonavir (RTV) (darunavir/RTV) with those of atazanavir/RTV on lipid and glucose parameters. METHODS Forty-nine HIV-negative, healthy male volunteers received RTV 100 mg once a day (qd) for 7 days, followed by either darunavir/RTV 800/100 mg qd (n=25) or atazanavir/RTV 300/100 mg qd (n=24) for 21 days. Mean changes in fasting… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…